Last Updated: 03/14/13
Diagnostics Evaluation Branch (DEB)
The Diagnostics Evaluation Branch (DEB) facilitates the development of markers and validation of innovative in vitro diagnostics to improve clinical outcomes for cancer patients.
Stimulating and supporting research to use in vitro diagnostics as prognostic markers to improve tumor classification and predictive markers to improve response to therapy.
Stimulating and supporting research on ELSI (ethical, legal and social implications) research considerations that include, but are not limited to: (i) informed consent, (ii) data access and data security, (iii) disclosure of research findings, and (iv) promoting community engagement of research participants.
Collaborating with other researchers and Government agencies to analytically and clinically validate in vitro diagnostics and their clinical utility.
DEB Staff:
| Name | Position | Primary Email | Phone |
|---|---|---|---|
| John Jessup, M.D. | Branch Chief | jessupj@mail.nih.gov | (240) 276-5952 |
| Magdalena Thurin, Ph.D. | Program Director | thurinm@mail.nih.gov | (240) 276-5973 |
| Kelly Kim, Ph.D. | Program Director | kimke@mail.nih.gov | (240) 276-5938 |
| Carol Weil, J.D. | Program Director | carol.weil@nih.gov | (240) 276-5975 |
| Acquilly Lionel | Administrative Support | acquilly.lionel@nih.gov | (240) 276-6005 |
